ClinicalTrials.gg
RecruitingNCT05700058ARLA-WHEYUpdated May 1, 2026

Assessing the Dose-response of Muscle Protein Synthesis to "Super-whey" in Older Adults

An interventional study of Dietary protein supplement in Sarcopenia, sponsored by University of Nottingham. Recruiting at 1 site in United Kingdom. Open to male participants aged 65 Years to 85 Years, including healthy volunteers. Per ClinicalTrials.gov, last updated 2026-05-01.

Sponsored by University of Nottingham · Not applicable, Interventional, and Other

How we know

From the registry’s dates

  • Started Jan 2023; still recruiting 3 years 9 months later.

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Not applicable
Study type
Interventional
Enrollment
30
Allocation
Randomized
Ages
65 Years to 85 Years
Sex
Male
01

Where this study stands

Counted across the records on this site · 2026-11-22

Among 14 studies in Sarcopenia by University of Nottingham — 2 open to participants now, 2 under way, none of them phase 3. Sarcopenia · University of Nottingham.

Planned enrollment
9th of 12
30 · median 32
Started
2023
the only one that year
No phase
11 of 14
2 open now
Registered
11th of 14
by date

Among the 14 studies in Sarcopenia by University of Nottingham, this one is the 9th largest by planned enrollment of the 12 interventional ones that give a count, is the only one that started in 2023, is one of 11 with no phase, and was the 11th registered.

Sarcopenia

1,334 studies on the registry are indexed under Sarcopenia; 418 are open to participants now.

Browse Sarcopenia studies →

Open to participants now

2 of the 14 studies in Sarcopenia by University of Nottingham are open now, in 1 country. Recruiting first, the newest first:

By country, each count listing its studies:

All 2 open studies →

Where they have run

Who these studies take

Of the 246 Sarcopenia studies recruiting now, 155 (63%) set no upper age limit and 32 (13%) stop at 75 or younger; 9 take children under 18; 62 take healthy volunteers.

This study: 65 Years to 85 Years · male · healthy volunteers too.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 14 studies in Sarcopenia by University of Nottingham, or all of them as a file.
02

Study summary

Skeletal muscle accounts for approximately 45-55% of total body mass in healthy adults and plays a pivotal role in whole-body metabolic health, locomotion and physical independence. Undesirable loss of skeletal muscle mass (atrophy) is, however, a common feature of many diseases and scenarios including ageing, bed rest/immobilisation, cancer and physical inactivity. Despite the exact mechanisms causing muscle atrophy being not yet fully understood, "anabolic resistance" (reduced muscle building in response to protein feeding and exercise) is thought to be key, especially for age-related skeletal muscle losses (known as sarcopenia). As such, the search for optimal strategies (e.g., exercise and/ or nutritional interventions) to combat this anabolic blunting remains a hot-topic in scientific research.

Leucine, an essential and branched chain amino acid (EAA/BCAA), is thought to be the most potent AA for stimulating muscle protein synthesis (MPS; the muscle building process). Although, as a stand-alone supplement, leucine is unlikely to provoke a robust and prolonged state of MPS, low doses of leucine-enriched mixed-EAAs can elicit similar increases in MPS as compared to a large dose of whey protein. As reduced appetite and increased satiety (feeling fuller) are common with advancing age, supplementation of a low-dose protein (i.e., leucine-enriched) that can adequately stimulate MPS may contribute to muscle health maintenance in older adults and reduce satiation following a meal.

This study aims to examine which of three doses of a novel leucine-enriched whey protein ("super-whey") best stimulates muscle building in older adults

03

Conditions studied

  • Sarcopenia

Browse trials for

04

Who can participate

Ages eligible
65 Years to 85 Years
Sexes eligible
Male
Accepts healthy volunteers
Yes

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Participant is in the desired age-ranges (young adults: 18-35 years; older adults: 65+ years).
  • Participant is willing and able to give for participation in the study.
  • Participant is physically able to perform resistance exercise

Exclusion criteria

Exclusion Criteria:

  • A \<18 or >35 kg/m2
  • Active cardiovascular, cerebrovascular or respiratory disease: e.g. uncontrolled hypertension (BP > 160/100), angina, heart failure (class III/IV), arrhythmia, right to left cardiac shunt, recent cardiac event, , pulmonary hypertension or recent (6 mo) stroke
  • Any metabolic disease
  • Clotting dysfunction
  • A history of, or current neurological or musculoskeletal conditions (e.g. epilepsy)
  • Lactose intolerance
  • Having taken part in a research study in the last 3 months involving invasive procedures or an inconvenience allowance
Terms in these criteria, in plain language(3)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

BMI (body mass index)

Weight in kilograms divided by height in metres squared. Example: 70 kg and 1.75 m gives 70 ÷ (1.75 × 1.75) ≈ 22.9.

What counts as overweight or obesity differs between countries (some use lower cut-offs), so go by the range the study states.

COPD

Chronic obstructive pulmonary disease: long-term lung disease that makes it hard to breathe out, including emphysema and chronic bronchitis.

05

Study design

Phase
Not applicable
Primary purpose
Other
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Double (Participant, Investigator)
Enrollment
30 participants (estimated)

Study arms

  • Experimental
    Super-Whey protein Dose 1

    All protein sources will be given in doses that are considered low/normal, both in relation to recommended dietary advice and commercially available supplements. As such, no adverse reactions or side effects are expected through consumption of these supplementations. This protein dose will be 5 g protein and will be given as a single bolus dose.

    Other: Dietary protein supplement

  • Experimental
    Super-Whey protein Dose 2

    All protein sources will be given in doses that are considered low/normal, both in relation to recommended dietary advice and commercially available supplements. As such, no adverse reactions or side effects are expected through consumption of these supplementations. This protein dose will be 10 g protein and will be given as a single bolus dose.

    Other: Dietary protein supplement

  • Experimental
    Super-Whey protein Dose 3

    All protein sources will be given in doses that are considered low/normal, both in relation to recommended dietary advice and commercially available supplements. As such, no adverse reactions or side effects are expected through consumption of these supplementations. This protein dose will be 20 g protein and will be given as a single bolus dose.

    Other: Dietary protein supplement

Interventions

  • OtherDietary protein supplement

    3 different doses of super-whey protein supplements will be given in a randomised crossover fashion to participants

06

What researchers measure

Primary outcomes

  1. Muscle protein fractional synthetic rate (postabsorptive)

    Postabsorptive measures of muscle protein synthesis assessed in muscle tissue (collected by muscle biopsy). This outcome will be assessed prior to administering a protein drink to obtain muscle protein fractional synthetic rate in the fasted state.

    Time frame: Assessed at 3 hour mark

  2. Muscle protein fractional synthetic rate (postprandial)

    Postprandial measures of muscle protein synthesis assessed in muscle tissue (collected by muscle biopsy). This outcome will be assessed following administering a protein drink to obtain muscle protein fractional synthetic rate in the fed state.

    Time frame: Assessed at 6 hour mark

Secondary outcomes

  1. Plasma amino acid concentrations

    During the fasted and fed states of the study, blood samples are collected every 20 minutes to capture the plasma amino acid concentrations in the blood at that time-point (24 timepoints assessed). Future analysis using mass-spectroscopy will allow determination of the different amino acid concentrations in the blood plasma collected.

    Time frame: Assessed over 7.5 hours

07

Study locations

1 of 1 sites recruiting
  • Centre of Ageing, Metabolism and Physiology
    Derby, DE22 3DT, United Kingdom
    Recruiting
08

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Started Jan 2023 (actual). Primary completion is estimated for Sep 2026, 44 months after the start.

Of 497 non-industry interventional studies with no phase under Sarcopenia, half reached primary completion within 18 months of starting (the median), counting those still running; a quarter within 8 and three quarters within 34. This study's planned 44 months is above that.

Counting every sponsor, half of 509 studies reached it within 18 months; a quarter within 8 and three quarters within 34.

How these figures are worked out, and which studies are left out of them.

Registered
Jan 17, 2023
First posted
Jan 26, 2023
StartActual
Jan 31, 2023
Primary completionEst.
Sep 2026
CompletionEst.
Oct 2026
Last update
May 1, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on May 1, 2026, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
09

Registry details

Key details

Study ID
NCT05700058
Responsible party
Philip Atherton (Professor, University of Nottingham) — Principal investigator
First posted
Jan 26, 2023
Start date
Jan 31, 2023
Primary completion
Sep 2026 (estimated)
Completion
Oct 2026 (estimated)
Last update
May 1, 2026

Oversight

Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Interested in this study?

Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.

No contact was published for this record. The registry link below has the sponsor’s details.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion